Evidence map›Paper›PMID 24875066›Full record

ArticleJournal of clinical psychopharmacology2014

Pro re nata (as needed) psychotropic medication use in patients with borderline personality disorder and subjects with other personality disorders over 14 years of prospective follow-up.

Eduardo Martinho, Garrett M Fitzmaurice, Frances R Frankenburg, Mary C Zanarini

Open access · greenAbstract read
In one paragraph

Article in Journal of clinical psychopharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. As-Needed Medication Use for Agitation Across Valproic Acid Formulations.Current therapeutic research, clinical and experimental · 2026
    Article
  2. Article
  3. What Works in the Treatment of Borderline Personality Disorder.Current behavioral neuroscience reports · 2017
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Eduardo MartinhoFrom the *McLean Hospital, Belmont, MA; †Department and Institute of Psychiatry, University of Sao Paulo Medical School, Sao Paulo, Brazil; ‡Harvard Medical School; and §School of Medicine, Boston University, Boston, MA.
Garrett M Fitzmaurice
Frances R Frankenburg
Mary C Zanarini
McLean Hospital · USHarvard University · US

Funding

MCLEAN STUDY OF ADULT DEVELOPMENTR01MH062169 · NIMH · MC LEAN HOSPITAL (BELMONT, MA) · PI ZANARINI, MARY C · 2000 to 2014
$6.6M
LONGITUDINAL COURSE OF BORDERLINE PERSONALITY DISORDERR29MH047588 · NIMH · MC LEAN HOSPITAL (BELMONT, MA) · PI ZANARINI, MARY C · 1992 to 1996
–
NIMH NIH HHS MH47588NIMH NIH HHS MH62169NIMH NIH HHS R01 MH062169
6 · The paper itself

Abstract

The use of pro re nata (PRN; as needed) psychotropic medication in patients with borderline personality disorder (BPD) has not been well characterized. This study had 3 purposes, which are as follows: (1) to describe the prevalence of PRN psychotropic medication use among patients with BPD and comparison subjects with other personality disorders (OPD) over 14 years of prospective follow-up, (2) to examine the rates reported by patients with BPD who ever recovered and never recovered, and (3) to examine the reasons for taking PRN medication reported by these patients. Overall, the prevalence of PRN psychotropic medication use was initially approximately 3 times higher among patients with BPD than comparison subjects with OPD, with a significant one-third decline in the use of PRN medication reported by patients with BPD over time. In analyses restricted to patients with BPD, patients with BPD who never recovered were approximately twice as likely to use PRN medication than patients with BPD who ever recovered over time. In reasons for use, the rates of PRN medication use to decrease agitation for both diagnostic groups declined significantly over time, whereas they remained significantly higher among patients with BPD. Likewise, patients with BPD who never recovered reported higher use of PRN medication to decrease agitation than patients with BPD who ever recovered over time. The results of this study indicate that PRN psychotropic medication is widely used for the treatment of patients with BPD, particularly those who have not achieved a recovery in both the symptomatic and psychosocial realms. They also suggest that patients with BPD use proportionally more PRN medication to decrease agitation than comparison subjects with OPD, with lower proportional use to reduce agitation found among recovered patients with BPD.

Indexed as

AdultBorderline Personality DisorderDrug Administration ScheduleFemaleFollow-Up StudiesHumansMalePersonality DisordersProspective StudiesPsychotropic DrugsSingle-Blind MethodYoung AdultPsychotropic Drugs

Identifiers

PMID24875066
PMCPMC4077949
OpenAlexW2000586718

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.